MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MACROGENICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.33+0.08 (+2.46%)
Close on Oct 19, 2026
- Market cap
- $211.77M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
100.0%+0.0 pts over 5 years
Operating margin
-48.7%+76.2 pts over 5 years
Net margin
-49.9%+73.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.3% | -0.5% | +7.3% | +4.0% | |
| Gross profit | +0.3% | +0.2% | +7.3% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -20.1% | -49.3% | -86.9% | |
| Return on assets | -17.5% | -37.5% | -28.8% | |
| Current ratio | 10.40 | 6.17 | 5.10 | |
| Interest coverage | – | – | -8.6× | |
| Inventory turnover | – | – | 0.0× | |
| Capex to revenue | 12.4% | 5.6% | 1.3% | |
| Diluted shares | 35M | 52M | 63M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Macrogenics generated $458.41M from operations and spent $17.21M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$458.41M
Used
$17.21M
Capital expenditure$17.21M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-49.9%
×Asset turnover0.58×
×Equity multiplier3.02×
=Return on equity, FY2025-86.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -49.9% | 0.58× | 3.02× | -86.9% |
| FY2024 | -44.7% | 0.54× | 2.08× | -49.9% |
| FY2023 | -15.4% | 0.20× | 1.96× | -6.1% |
| FY2022 | -78.8% | 0.49× | 1.61× | -62.8% |
| FY2021 | -261.0% | 0.22× | 1.33× | -75.5% |
| FY2020 | -123.7% | 0.30× | 1.31× | -49.3% |
| FY2019 | -236.5% | 0.20× | 1.36× | -64.1% |
| FY2018 | -285.2% | 0.17× | 1.30× | -63.3% |
| FY2017 | -12.4% | 0.46× | 1.21× | -6.9% |
| FY2016 | -63.7% | 0.27× | 1.15× | -20.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$74.62M
- Cash generatingOperating cash flow above zero-$81.04M
- Return on assets improvedROA up on the prior year-22.4% → -28.5%
- Earnings backed by cashOperating cash flow above net income-$81.04M vs -$74.62M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.92 → 5.10
- No dilutionShare count did not rise63M → 63M
- Gross margin improvedGross margin up on the prior year99.44% → 100.00%
- More efficientAsset turnover rose0.50 → 0.57